Celldex Therapeutics, Inc. Share Price Nasdaq
Stocks
US15117B1035
Biotechnology & Medical Research
| Market Cap | 307.21Cr 264.14Cr 248.5Cr 226.77Cr 423.2Cr 29TCr 425.39Cr 2.94TCr 1.14TCr 15TCr 1.15TCr 1.13TCr 47TCr | P/E 2026 * |
-9.32x | P/E 2027 * | -9.23x |
|---|---|---|---|---|---|
| Enterprise Value | 240.98Cr 207.19Cr 194.92Cr 177.88Cr 331.96Cr 23TCr 333.68Cr 2.31TCr 893.54Cr 12TCr 904.89Cr 885.13Cr 37TCr | EV / Sales 2026 * |
1,186x | EV / Sales 2027 * | 191x |
| Free-Float |
99.73% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Celldex Therapeutics, Inc.
| 1 day | +10.82% |
| Manager | Title | Age | Since |
|---|---|---|---|
Tibor Keler
CTO | Chief Tech/Sci/R&D Officer | 67 | 30/07/2014 |
Anthony Marucci
CEO | Chief Executive Officer | 64 | 01/09/2008 |
Sam Martin
DFI | Director of Finance/CFO | 55 | 01/04/2009 |
| Director | Title | Age | Since |
|---|---|---|---|
Anthony Marucci
BRD | Director/Board Member | 64 | 01/12/2008 |
Harry Penner
CHM | Chairman | 80 | 05/06/2025 |
Herbert Conrad
BRD | Director/Board Member | 93 | 01/03/2008 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.82% | +992.89% | - | - | 307.21Cr | |
| -0.85% | -5.49% | -2.99% | +13.18% | 4.8TCr | |
| -1.29% | -1.22% | +404.92% | +545.45% | 4.44TCr | |
| -3.20% | +0.33% | +38.11% | +21.39% | 4.27TCr | |
| -1.89% | -2.00% | +1.45% | +82.46% | 4TCr | |
| -1.72% | -2.61% | +13.09% | +42.33% | 3.28TCr | |
| -0.17% | +3.78% | - | - | 1.77TCr | |
| -0.07% | +1.32% | +20.08% | +117.95% | 1.65TCr | |
| +0.03% | -2.17% | +11.32% | +31.41% | 1.44TCr | |
| -2.68% | -0.56% | +73.31% | +40.56% | 1.34TCr | |
| Average | -0.11% | -0.48% | +69.91% | +111.84% | 3TCr | |
| Weighted average by Cap. | -1.37% | -1.05% | +85.04% | +132.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 20.31L 17.46L 16.43L 14.99L 27.98L 19Cr 28.13L 1.95Cr 75.32L 9.84Cr 76.27L 74.61L 31Cr | 1.27Cr 1.09Cr 1.03Cr 93.96L 1.75Cr 120.67Cr 1.76Cr 12Cr 4.72Cr 62Cr 4.78Cr 4.68Cr 196.27Cr |
| Net income | -32Cr -27Cr -26Cr -24Cr -44Cr -3.03TCr -44Cr -305.9Cr -118.35Cr -1.55TCr -119.85Cr -117.24Cr -4.92TCr | -36Cr -31Cr -29Cr -27Cr -50Cr -3.42TCr -50Cr -345.93Cr -133.84Cr -1.75TCr -135.54Cr -132.58Cr -5.57TCr |
| Net Debt | -66Cr -57Cr -54Cr -49Cr -91Cr -6.28TCr -92Cr -634.78Cr -245.59Cr -3.21TCr -248.71Cr -243.28Cr -10TCr | -64Cr -55Cr -52Cr -47Cr -88Cr -6.04TCr -88Cr -611.04Cr -236.4Cr -3.09TCr -239.41Cr -234.18Cr -9.83TCr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
